Mitochondrial and Peroxisomal Alterations Contribute to Energy Dysmetabolism in Riboflavin Transporter Deficiency

Fiorella Colasuonno,1 Alessia Niceforo,1,2 Chiara Marioli,3 Anna Fracassi,1,4 Fabrizia Stregapede,1,2 Keith Massey,5 Marco Tartaglia,3 Enrico Bertini,2,3 Claudia Compagnucci,3 and Sandra Moreno1

1Department of Science, LIME, University of Roma Tre, Rome 00146, Italy
2Department of Neuroscience, Unit of Neuromuscular and Neurodegenerative Diseases, Laboratory of Molecular Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
3Genetics and Rare Diseases Research Division, IRCCS Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
4Mitchell Center for Neurodegenerative Diseases, Department of Neurology, University of Texas Medical Branch, Galveston, 77550 TX, USA
5Cure RTD Foundation, Calgary, Alberta, Canada

Correspondence should be addressed to Claudia Compagnucci; claudia.compagnucci@opbg.net and Sandra Moreno; sandra.moreno@uniroma3.it

Received 11 May 2020; Revised 7 July 2020; Accepted 13 July 2020; Published 13 August 2020

Academic Editor: Francesca Danesi

Copyright © 2020 Fiorella Colasuonno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Riboflavin transporter deficiency (RTD) is a childhood-onset neurodegenerative disorder characterized by progressive pontobulbar palsy, sensory and motor neuron degeneration, sensorineural hearing loss, and optic atrophy. As riboflavin (RF), also known as vitamin B2, is the precursor of all biologically important flavins, and it is widely distributed throughout the plant and animal kingdoms [2]. Flavins are broadly distributed in tissues, but the majority is found in flavo-coenzymes, mainly as flavin adenine dinucleotide (FAD) and in lesser amounts as flavin mononucleotide (FMN).

1. Introduction

Flavins are a family of ubiquitous water-soluble compounds, sharing the basic structure of 7,8-dimethyl-10-alkylisoalloxazine and participating in many biochemical reactions as coenzymes [1]. Riboflavin (RF), also known as vitamin B2, is the precursor of all biologically important flavins, and it is widely distributed throughout the plant and animal kingdoms [2]. Flavins are broadly distributed in tissues, but the majority is found in flavo-coenzymes, mainly as flavin adenine dinucleotide (FAD) and in lesser amounts as flavin mononucleotide (FMN).
Ever since their discovery and characterization, RF and its derivatives have been recognized by their ability to transfer single electrons, hydrogen atoms, and hydride ions, thus making flavoenzymes highly versatile, in terms of substrate modifications and types of reactions. The direct involvement of FAD and FMN, as rate limiting factors in energy metabolism, is widely accepted, as well as the direct correlation between the rate of cellular energy metabolism and the levels of FAD and FMN [3–5].

RF is essential for a wide variety of reactions, which preferentially occur in mitochondria [6, 7]. The oxidative metabolism of carbohydrates, fatty acids, amino acids, choline, and several other bioenergetically relevant metabolites depends on flavoproteins functionality. Specifically, subunits of the respiratory chain complexes I and II, as well as the electron transfer flavoprotein and its ubiquinone oxidoreductase, localized to the inner mitochondrial membrane, drive electrons from several reduced flavoproteins to ubiquinone and then to complex III of the respiratory chain [8].

Several metabolic pathways depending on flavoprotein functionality occur in peroxisomes, which contain more than 50 flavoenzymes functioning in crucial steps of anabolic and catabolic reactions [9]. Peroxisomes play key cooperative roles in the metabolism of cellular lipids and reactive oxygen species (ROS), making them indispensable for human development and health [10]. Mammalian peroxisomes contribute to the breakdown and detoxification of fatty acids (via fatty acid α and β-oxidation); the synthesis of ether-phospholipids (e.g., myelin sheath lipids), bile acids, and docosahexaenoic acid; glyoxylate metabolism; amino acid catabolism; polyamine oxidation; and reactive nitrogen species (RNS) metabolism [11]. Over the last decades, peroxisome crosstalk with mitochondria, the endoplasmic reticulum, lipid droplets, lysosomes, and phagosomes has received growing attention [12]. Recent evidence also indicates functional interplay between peroxisomes and the nucleus, which may also involve signaling via H2O2 [13].

Mammals, including humans, have lost the ability to synthesize water-soluble vitamins, and they obtain these compounds from exogenous sources to prevent clinical signs of deficiency [14], the minimal requirement for RF being around 0.35 mg/1,000 kcal. Absorption in mammals takes place mainly in the small intestine and partly in the large intestine [8]. The physiological mechanisms regulating RF uptake by the different mammalian organs and tissues are only partially understood, but it has recently been demonstrated that RF transport is carrier mediated [8, 15, 16].

Three human riboflavin transporters belonging to the SLC52 family of solute carriers have been characterized. Recent nomenclature refers to them as hRFVT1, hRFVT2, and hRFVT3, encoded by the SLC52A1, SLC52A2, and SLC52A3 genes [15, 16]. hRFVT1 and hRFVT2 proteins share 86% amino acid identity, while they only exhibit 42% and 43% identity with hRFVT3, respectively. The three proteins have partially overlapping subcellular and tissue-specific expression profiles. Both hRFVT2 and hRFVT3 are widely distributed, with hRFVT3 having the highest expression in the testis, small intestine, kidney, and placenta and hRFVT2 having the highest expression in the brain and spinal cord [17–19]. In contrast, hRVFT1 has little expression in the central nervous system with the highest expression in the small intestine and placenta [20]. They are predicted to have 10 (hRFVT1 and 2) or 11 (hRFVT3) membrane-spanning domains [21].

A clinically wide spectrum of human diseases has been associated with defective function of flavoproteins, including Leigh syndrome and other mitochondrial respiratory chain disorders, mitochondrial and peroxisomal fatty acid oxidation (FAO) disorders, pyridoxal phosphate responsive epilepsy, trimethylaminuria, rhizomelic chondrodysplasia punctata, porphyria variegate, chronic granulomatous disease, and defects of steroidogenesis and bile acid synthesis [5].

RF deficiency during pregnancy and adolescence may be related to developmental abnormalities and to an increased risk for anemia, cancer, and cardiovascular and neurodegenerative diseases [22]. Moreover, human metabolic diseases affecting nervous and muscular systems are caused by flavoprotein derangements or inadequate availability of flavin cofactors caused by genetic mutations [3, 23]. Among these, there are the RF-responsive multiple Acyl-CoA dehydrogenase deficiency, the Fazio-Londe syndrome, and the riboflavin transporter deficiency (RTD).

RTD syndrome, formerly known as Brown-Vialetto-Van Laere (BVVL) syndrome, is a rare autosomal-recessive motor neuron disease. Typical clinical features reported include pontobulbar palsy, limb and axial muscle weakness, sensori-neural hearing loss, optic atrophy, ataxia, and respiratory compromise [24, 25]. The age of onset is variable, and young patients show different phenotypes with variable prognosis, often influenced by the initiation of RF treatment. In fact, clinical evidence brought by Bosch and coll. [23] argues for partial amelioration of the pathological phenotype of RTD patients, after high-dose vitamin B2 administration.

Numerous mutations in SLC52A2 and SLC52A3 have been recognized as causative for the childhood-onset RTD syndrome [26]. Lack of association of a pathological condition with mutations in SLC52A1 likely indicates an indispensable role of this transporter early in development [16, 27].

When SLC52A2 and SLC52A3 RF transport into the cell is reduced, its limited availability can compromise several vital processes [28, 29]. It is therefore likely that mitochondrial and peroxisomes are impaired in their integrity and bioenergetics in RTD syndrome. Unfortunately, in vivo models for RTD, recapitulating symptoms and progression, are so far lacking. RF-deficient mouse models have been generated but are characterized by embryonic or early postnatal lethality, which does not allow studies on the pathological phenotype [30, 31].

In the present work, we took advantage of the induced pluripotent stem cell (iPSC) technology to shed light on the molecular mechanisms and dysfunctional cellular processes underlying this severe neurological disorder. Such technology is well consolidated in biomedical research, since it allows the development of patient-specific cellular models, generally preserving genome integrity [32], even in the presence of epigenetic remodeling [33]. On the other hand,
morphofunctional changes occurring in cytoplasmic organelles, particularly mitochondria, during cell reprogramming and maintenance, are now widely characterized, allowing the researchers to make comparisons between healthy and diseased conditions [34–36].

Human iPSCs from RTD patients carrying SLC52A2 gene mutations were characterized, focusing on mitochondrial and peroxisomal alterations. The characterized morphological, ultrastructural, and molecular endophenotype was used to assess the effects of RF supplementation as treatment to rescue such dysfunctions. These experiments were aimed at providing the mechanistic basis at the cellular level for the efficacy of symptomatic, empirical therapies proposed for RTD [23, 37–43].

2. Materials and Methods

2.1. Derivation of iPSCs and Treatment. Human iPSCs were derived from fibroblasts of healthy subjects and two RTD patients carrying SLC52A2 gene mutations (c.155C>T and c.935T>G; c.155C>T and c.1255G>A). One patient (P1) presented at 3 months of age with macrocytic anemia and dysphagia. Optic atrophy, axial muscle weakness, sensory ataxia, and respiratory compromise were noted at 1 year and bilateral sensorineural hearing loss at 2 years. Patient P1 is 9 years old and appears neurologically stable since beginning riboflavin therapy at 2.5 years of age. The second patient (P2), as reported by Ciccolella and coll. [44], developed progressive dysphonia and notable exercise intolerance with dyspnea and cyanosis at 2 years, bilateral sensorineural hearing loss, reduced visual acuity, and progressive shoulder and axial muscle weakness at 3 years. Before the 4th year, P2 required hospitalization for acute respiratory failure and aspiration pneumonia and after a few days, the patient died [44].

Fibroblasts were reprogrammed by using the nonintegrating episomal technology (Epi Episomal iPSC Reprogramming Kit, Cat. no. A15960, ThermoFisher Scientific, Waltham, MA, USA) by System Biosciences (Palo Alto, CA, USA). Cells were grown under feeder-free conditions, using Matrigel (BD Biosciences, NJ, USA) in mTeSR1 (Stem Cell Technologies Inc.), and incubated at 37°C, in hypoxic conditions.

Control (Ctrl) and patients’ iPSCs were treated with the culture medium supplemented or not with 1 μM RF (R9504, Sigma-Aldrich, St. Louis, MO, USA) overnight.

2.2. DNA Sequencing. Ctrl and RTD iPSC pellets, obtained by centrifuging EDTA-detached cells at 1200 rpm for 5 min, were processed for genomic DNA extraction (Qiagen, Hilden, Germany) following the manufacturer’s instructions.

The coding sequence of exons 3 and 5 of the SLC52A2 gene (NM_001363118) was amplified by PCR specific primers. Amplimers were purified using Exo-SAP (GE Healthcare) and directly sequenced using BigDye 3.1 chemistry (Applied Biosystems, Foster City, CA, USA) with an ABI Prism 3130 xl automatic sequencer (Applied Biosystems).

2.3. Light and Confocal Microscopy. General morphological features of cell cultures were assessed by an inverted microscope Olympus IX Leica (Tokyo, Japan), equipped with IAS 2000 image capturing software.

For confocal analysis, cells were fixed with 4% paraformaldehyde for 10 min at room temperature (RT), washed with PBS, and blocked with 5% bovine serum albumin and 0.1% Triton X-100 (Sigma-Aldrich). Polyclonal or monoclonal primary antibodies against the following are used: peroxisomal markers (1:200 catalase (anti-CAT, 100-4151, Rockland Immunochemicals, Inc., Limerick, PA, USA), 1:250 acyl-CoA oxidase (anti-ACOX, ab184032, Abcam, Cambridge, UK), 1:200 GSH, 101-A, Virogen, Watertown, MA, USA), and 1:100 GSH, 101-A, Virogen, Watertown, MA, USA), and 1:100 zonula occludens-1 (anti-ZO-1 (33–9100, ThermoFisher Scientific)).

After washings in PBS, cells were incubated for 1 h with the appropriate secondary antibodies, conjugated with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen, Carlsbad, CA, USA), and diluted 1:500 in PBS. Nuclei were stained with 1 μg/ml Hoechst (33342, Invitrogen) for 10 min at RT, and coverslips were mounted using 1:1 PBS/glycerol. Slides were observed in a Leica TCS SP5 confocal microscope (Leica, Wetzlar, Germany). Representative images, captured by a Leica Application Suite software, were composed in an Adobe Photoshop CS6 format (Adobe Systems Inc., San Jose, CA, USA).

2.4. Ultrastructural Analyses. For focused ion beam/scanning electron microscopic (FIB/SEM) analyses, cells were plated and treated in a chamber slide (Lab-Tek™ II Chamber Slide System, ThermoFisher Scientific) and fixed in 0.5% glutaraldehyde and 2% paraformaldehyde, in 0.1 M cacodylate buffer, pH 7.4, for 1 h, at 4°C. Postfixation with osmium tetroxide, dehydration, and embedding in epoxy resin were performed as previously described [45]. Resin-embedded cells were mounted on stubs using a self-adhesive carbon disk and gold sputtered by an Eemitc K550. Samples were then analyzed by a DualBeam FIB/SEM (Helios Nanolab, FEI, Hillsboro, OR, USA). Regions of interest were cross sectioned by the focused gallium ion beam of the device. Micrographs were acquired at a working distance of 2 mm using backscattered electrons and a through-the-lens detector in immersion mode with an operating voltage of 2 kV and an applied current of 0.17 nA.

For SEM analysis, cells were plated on glass slides; fixed in 2.5% glutaraldehyde, for 1 h; postfixed in 1% osmium tetroxide, for 45 min; and gradually dehydrated (from 50% to 100% ethanol). Air drying was performed using hexamethyldisilazane and, once mounted on stubs, a sputter coater was used to make the sample properly conductive. Micrographs were acquired at a working distance of 2 mm using backscattered electrons and both Everhart-Thornley and
through-the-lens detectors (ETD and TLD) with an operating voltage of 2 kV and an applied current of 0.34 nA. Images were assembled in Adobe Photoshop CS6 software (Adobe Systems Inc.).

2.5. MitoSOX Red Assay. Detection of O$_2^-$ was performed by MitoSOX Red Mitochondrial Superoxide Indicator (Molecular Probes, Eugene, OR, USA). This fluorogenic dye for highly selective detection of O$_2^-$ in the mitochondria measures the fluorescence intensity increase (emission: ~510/580 nm). Cells were preliminarily detached with EDTA, centrifuged at 1200 rpm for 5 min, washed in PBS, and solubilized in Mitochondria Incubation Buffer (Molecular Probes). Cells were incubated with 5 μM MitoSOX Red Probe for 45 min at 37°C. The fluorescence intensity was measured by an EnSpire Multimode Plate Reader (Perkin Elmer, Boston, MA, USA). Data were normalized based on protein amount determined by the bicinchoninic acid assay (Pierce BCA Protein Assay Kit, ThermoFisher Scientific).

2.6. JC-1 Staining. 5,5,6,6′-Tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine chloride (JC-1) (T3168, Life Technologies, Carlsbad, CA, USA) probe was used to monitor mitochondrial membrane potential (MMP), according to the manufacturer’s instructions. Cells were grown in mTeSR1 and treated with 5 μM JC-1 for 30 min at 37°C. After washing twice with mTeSR1, cells were photographed before and after 1, 5, 10, 15, and 30 min following 10 μM H$_2$O$_2$ exposure. Regions of high mitochondrial polarization are revealed by red fluorescence due to J-aggregate formation of the concentrated dye, whereas depolarized regions are indicated by green fluorescence of JC-1 monomers. Pictures are representative images of four experiments performed in live imaging condition using an inverted Leica DMi8 microscope (Leica, Carlsbad, CA, USA). The time course of iPSCs before and during H$_2$O$_2$ treatment shows the fluorescence intensity ratio for JC-1 staining (red/green fluorescence intensity ratio).

2.7. Statistical Analysis. For mitochondrial morphometric analyses, 3 samples/cell culture type and 10 cells/sample were analyzed by manually counting regular and altered mitochondria of Ctrl and RTD iPSCs and calculating their respective percentage. The mean diameter of mitochondria was obtained by manually measuring the organelles in the same samples.

Statistical analysis was performed using Prism software (GraphPad Software, Inc., La Jolla, CA, USA). The results are presented as means ± SD of $n \geq 3$ independent experiments.

For MitoSOX Red assay, Mann-Whitney test was used. For all the other data, one-way ANOVA was used to analyze differences among genetic conditions and treatments, followed by Tukey’s multiple comparison test or Bonferroni test, as appropriate. A $p$ value of 0.05 or less was considered statistically significant (*), while ** and *** indicate $p$ values equal or lower than 0.01 and to 0.001, respectively.

Diagrams were assembled using PowerPoint and Photoshop CS6.

3. Results and Discussion

3.1. Results. The morphofunctional features of iPSCs from two RTD patients, carrying composite heterozygous mutations (c.155C>T and c.935T>G; c.155C>T and c.1255G>A) in the SLC52A2 gene were examined. The identified mutations were confirmed by Sanger sequencing on DNA extracted from RTD iPSC pellets, while Ctrl is negative for the mutations (Figure 1).

Morphological studies were performed by a panel of light and electron microscopic techniques. These were followed by functional analyses, with molecular probes, focusing on mitochondrial and peroxisomal compartments.

3.1.1. Phase-Contrast, Confocal, and Electron Microscopic Analyses of iPSCs. When compared to Ctrl cells, patient-derived iPSC cultures exhibit morphological defects, including absence of typical, roundly shaped colonies, and large extracellular spaces (Figure 2(a)). Spatial relationships among cells were further inspected by confocal immunofluorescence analysis using anti-ZO-1 (Figure 2(b)). While regular distribution of this tight junction protein at plasma membranes level is detected in Ctrl cells, unusual localization in few, large puncta or aggregates is observed in P1 cells (arrows in (ii)), and almost lack of staining is found in P2-derived cells. These abnormalities are even more apparent in higher magnification micrographs, showing details of ZO-1 distribution (Figure 2(b) (iv–vi)). Accordingly, statistical analysis demonstrates significantly lower ZO-1 fluorescence intensity in cell cultures from both patients, with respect to Ctrl cells (Figure 2(c)).

Scanning electron microscopy (SEM) was also used to analyze details of RTD iPSC surface (Figure 3). Unlike Ctrl iPSCs, patient-derived iPSC cultures organize in small colonies (mostly in P1) or as single cells (mostly in P2), often extending lamellipodia (in both P1 and P2), to form focal adhesions with the substrate. P1 cells generally appear more flattened in shape, while P2 cells show a more roundish shape with several vesicles (~1 μm in diameter) budding from the membrane. Accumulation of extracellular vesicles in acinariform aggregates at the apical cell surface is also observed, particularly in P2 (Figure 3 (vii–viii)). Consistent with the above morphological results, focused ion beam/scanning electron microscopy (FIB/SEM) reveals abnormal cell-cell contacts in RTD iPSC cultures, as compared to Ctrl (Figure 4(a)). Different from the long stretches of juxtaposed plasma membranes, with recognizable tight junctions (arrowheads in (i) and (ii)) shown by healthy cells, loose cell-cell contacts with few adherent junctions are displayed by P1 and P2 cells, with large intercellular spaces characterizing both cell lines (asterisks in (iv) and (vii)). Extracellular vesicles, in proximity to plasma membrane protrusions, are often observed (higher magnification micrographs in (vii) and (viii)). Moreover, membrane-limited cell
fragments containing nuclear parts (white arrow in (ii)) are found in RTD cultures.

Ultrastructural analysis also highlights marked mitochondrial abnormalities associated to the RTD phenotype, involving shape, number, and intracellular distribution. These organelles appear elongated, sometimes swollen, with disrupted or even absent cristae (Figure 4(a) (iv–ix)). All these features are lacking in Ctrl cells, which instead display roundly shaped, small, immature mitochondria with poorly-developed cristae (Figure 4(a) (i–iii)). Notably, mitochondria of patients’ iPSCs appear more dispersed in the cytoplasm, as compared to those of Ctrl cells, which are mainly localized near the nucleus. Statistical analysis to evaluate the occurrence of normal and altered mitochondria and their average size was also performed (Figures 4(a)–4(d)). Data demonstrate the presence of significantly more numerous mitochondria in patient’s cells (p < 0.05) and significantly higher number of damaged mitochondria (p < 0.01), in RTD vs. Ctrl cells. Patients’ organelles are also significantly larger than those of Ctrl cells, as assessed by measuring their mean diameter.

Aiming to further study mitochondrial distribution in our cell model, immunofluorescence with MTCO2 mitochondrial antibody was performed. Confocal analysis confirms uneven distribution and significantly greater number of these organelles in patients’ cells as compared to Ctrl (Figure 5). Specifically, while P1 iPSCs show dispersed puncta, P2 cultures show immunoreactive aggregates, at a pole of the cells (arrowheads in Figure 5(a)).

3.1.2. Study of Antioxidant Response of RTD iPSCs. Based on ultrastructural and confocal observations, showing deranged mitochondrial features, we studied the immunofluorescence localization of Mn-dependent superoxide dismutase (MnSOD, SOD2), for its dual value as a functional mitochondrial marker and as a major ROS-scavenging enzyme. Confocal analysis reveals a significant decrease of the antioxidant enzyme in RTD iPSCs compared to Ctrl cells, which show abundant particulate SOD2 immunopositivity (Figures 6(a) and 6(b)). To gain further insights into the antioxidant response ability of RTD cells, we investigated the immunofluorescence distribution of glutathione (GSH), Cu/Zn superoxide dismutase (SOD1), and catalase (CAT). Quantification analyses reveal significantly lower expression levels of GSH in RTD than in Ctrl cells, while higher levels of SOD1 and CAT are detected (Figure 6(b)). Morphologically, SOD1 shows the typical cytoplasmic distribution, irrespective of the genotype, while GSH appears abundantly diffused in the cytoplasm of Ctrl cells and occasionally concentrated in small aggregates in RTD iPSCs. Notably, CAT localization in diseased iPSCs unexpectedly extends from peroxisome-like granules, to the cytosolic compartment.

3.1.3. Study of Peroxisomal Proteins in RTD iPSCs. Considering RTD-associated abnormal distribution of CAT, a bona fide peroxisomal marker, we were prompted to extend our study to other peroxisomal markers. We chose to examine the fatty acyl translocator peroxisomal membrane protein of 70 kDa (PMP70), the first and rate-limiting enzyme of β-oxidation pathway Acyl-CoA Oxidase (ACOX-1), and the peroxisomal thiolase acetyl-CoA acyltransferase 1 (ACAA1), which catalyzes the last step of the cycle (Figure 7). Immunofluorescence data demonstrate downregulation of PMP70 and ACOX-1 in patients’ cells, while ACAA1 shows quantitatively unchanged levels of expression. Interestingly, the immunofluorescence
distribution of thiolase shows a more aggregated form, rather than the expected small granular localization (insets in Figure 7(a)).

Overall, these results are also consistent with our ultrastructural observations, suggesting the presence of fewer peroxisomes in RTD iPSCs, as compared to Ctrl cells (see Figure S1).

3.1.4. Effect of RF Treatment on iPSC Morphology and Redox Status. Since empirical studies have demonstrated some

---

**Figure 2:** Morphological features of Ctrl and RTD iPSCs. (a) Phase contrast images show absence of typical colonies in diseased cells as compared to controls. Scale bars, 20 \( \mu \)m. (b) Confocal analysis after immunofluorescence using ZO-1 marker (green) demonstrates abnormal cell-cell contacts in RTD (ii, iii, v, and vi) as compared to Ctrl (i, iv) iPSC. White arrows indicate ZO-1 aggregates in RTD iPSCs P1 (vi, vii) while white arrowheads indicate immunofluorescence puncta (v, vi). Scale bars, 10 \( \mu \)m (i–iii), 5 \( \mu \)m (iv–vi). Nuclei are stained with Hoechst (blue). (c) Fluorescence intensity levels reveal a significant decrease of ZO-1 expression in RTD vs. Ctrl iPSCs (***)\( p \leq 0.001 \).
amelioration of symptoms in patients treated with RF, we investigated possible beneficial effects of vitamin administration to RTD iPSCs. Based on preliminary experiments to test dose/response effect of RF treatment, we selected 1 μM concentration, as the most promising dosage to be added to the medium, in terms of tolerance and detoxifying action (Suppl. Figure 2).

Indeed, FIB/SEM micrographs show partial rescue of morphology following such treatment, as regular mitochondrial shape and features, comparable to Ctrl cells, are observed in RF-treated RTD iPSCs (Figure 8(a)).

For functional characterization of the diseased phenotype and possible rescue by RF, we also addressed RTD-associated redox status, by evaluating the presence of superoxide anion (O$_2^-$), using the MitoSOX Red probe, in iPSCs, before and after RF treatment. Statistically significant changes ($p < 0.01$) in O$_2^-$ concentration in patients’ iPSCs, as compared to Ctrl cells, are detected (Figure 8(b)). These alterations revert to normal levels following RF treatment.

Furthermore, mitochondrial membrane potential (MMP) in Ctrl and RTD iPSCs was determined using JC-1 staining, under basal conditions and after H$_2$O$_2$ exposure. These experiments were performed before and following RF treatment. Images in Figure 9(a) show a time-dependent loss of red J-aggregate fluorescence and cytoplasmic diffusion of green monomer fluorescence, following treatment with H$_2$O$_2$ (after 1, 5, 10, 15, and 30 minutes). These data show significantly abnormal polarization state of RTD mitochondria, as compared to Ctrl, even though the two patients exhibit opposite trends, i.e., depolarization in patient 1 and hyperpolarization in patient 2 (Figure 9). Improvement of MMP in RTD cells after RF treatment is observed, particularly in P2, which shows more efficient response to H$_2$O$_2$, similar to Ctrl iPSCs (Figure 9(b)).
Figure 4: Ultrastructural features of Ctrl and RTD iPSCs. (a) FIB/SEM micrographs showing abnormal cell-cell contacts in RTD iPSC cultures (iv, vii), as compared to Ctrl cells (i, ii) which display recognizable tight junctions (black arrowheads in (i) and (ii)). RTD cell cultures display loose cell-cell contacts and large intercellular spaces (asterisks in (iv) and (vii)). White arrowheads indicate extracellular vesicles, in proximity to plasma membrane protrusions in RTD cells (iv–vii); white arrow in (iv) indicates a membrane-limited cell fragment containing nuclear parts. Ctrl iPSCs show few healthy immature mitochondria with poorly developed cristae (ii, iii) while several damaged organelles with disrupted cristae are observed in RTD iPSCs (P1 and P2) (v, vi, viii, and ix). N: nuclei; m: mitochondria; rer: rough endoplasmic reticulum. Scale bars, 2 μm in (i), (iv), and (vii); 1 μm in (ii), (v), and (viii); 0.5 μm in (iii), (vi), and (ix). (b) Mitochondria are significantly more numerous in patients’ iPSCs than in Ctrl. (c) Patients’ iPSCs show a significantly higher number of damaged mitochondria, compared to Ctrl. (d) Mitochondrial average size is significantly larger in patients’ iPSCs than in Ctrl.
4. Discussion

Riboflavin (RF) represents an indispensable nutrient for human health, as a crucial component of cellular biochemistry. Indeed, knowledge of clinical implications of its dysmetabolism is attracting growing interest. On the one hand, RF deficiency, due to either insufficient intake or disturbances in its absorption or transport, results in severe clinical conditions, while on the other, a wide array of disorders affect RF-dependent metabolic pathways. The vitamin impacts on homeostatic control of energy balance, particularly involving lipid metabolism, and redox status. RF may even exert a direct antioxidant role through its conversion of reduced to oxidized form or as a component of glutathione redox cycle [46]. RF deficiency compromises oxidant defense mechanisms by interfering with the maintenance of reduced glutathione (GSH), the master antioxidant within cells [47]. Thus, RF nutritional status impacts directly on maintaining lipid metabolism, energy metabolism, and redox balance [3]. Besides its direct metabolic role, RF acts as a regulator of gene expression at different levels, transcriptional, posttranscriptional, translational, and posttranslational [48, 49]. Interestingly, cell death and survival pathways, as well as energy metabolism, are specifically subjected to such regulation.

In the last decade, mutations in the human RF transporter genes SLC52A2 (encoding for RFVT2) and SLC52A3 (encoding for RFVT3) were demonstrated as causative factor for a neurodegenerative disorder referred to as riboflavin transporter deficiency (RTD), formerly known as Brown-Vialetto-Van Laer syndrome [27].

Even though several in vivo and in vitro models have been developed to dissect the molecular mechanisms underlying RF deficiency [50–52], the involvement of energy metabolism pathways occurring in specific organelles is still unclear. In the present study, we took advantage of iPSC technology, to reproduce RTD phenotype in a patient-specific cellular model.

More specifically, iPSCs derived from two patients carrying different mutations on the SLC52A2 gene were studied...
from a morphofunctional viewpoint. Prior to proceeding with characterization of diseased vs. healthy iPSCs, we validated our model by DNA sequencing, demonstrating that RTD-associated mutations are maintained following reprogramming of fibroblasts into iPSCs. This result is in keeping with the available literature confirming dependability of iPSC technology in preserving genome integrity [32].

Overall, our data on patients’ specific iPSCs demonstrate substantial defects, which may be partially reverted by RF treatment. Such abnormalities include (i) aberrant cell-cell contacts and consequent inability of cells to organize into colonies; (ii) mitochondrial dysfunction associated with ultrastructural abnormalities; (iii) altered expression of antioxidant systems; and (iv) peroxisomal alterations.
4.1. RTD Results in Altered Cell-Cell Contacts. As assessed by phase-contrast and electron microscopy, patients’ iPSCs are unable to form regularly shaped colonies, which are instead a hallmark in iPSC cultures from healthy individuals. Lack of tight junctions and/or zonulae adhaerentes observed at the ultrastructural level is consistent with immunofluorescence results using the ZO-1 antibody. Indeed, confocal microscopic analysis demonstrates decreased expression and abnormal localization of this tight junction marker. Lower levels of the protein (especially in iPSCs from Ctrl iPSCs RTD iPSCs P1 RTD iPSCs P2 ACAA1/Hoechst ACOX-1/Hoechst PMP70/Hoechst Ctrl iPSCs RTD iPSCs P1 RTD iPSCs P2 ACAA1/Hoechst ACOX-1/Hoechst PMP70/Hoechst Ctrl iPSCs RTD iPSCs P1 RTD iPSCs P2 ACAA1/Hoechst ACOX-1/Hoechst PMP70/Hoechst (a) (b) Figure 7: Confocal analysis of peroxisomal markers in Ctrl and RTD cells. (a) Immunofluorescence images showing finely granular immunoreactivity to PMP70 and ACOX-1, of lower intensity in RTD patients, as compared to Ctrl cells. ACAA1 distribution appears more diffuse in RTD cells (insets). Peroxisomal proteins are marked by green fluorescence, while nuclei are stained with Hoechst (in blue). (b) Fluorescence intensity analyses show statistically different expression levels of peroxisomal markers. *p ≤ 0.05 vs. Ctrl iPSCs; **p ≤ 0.01 vs. Ctrl iPSCs.
patient 2) may result from oxidative damage due to increased ROS production, as supported by our MitoSOX data. This interpretation would be in keeping with observations by other groups on different iPSC models of degeneration [53], showing tight junction instability and altered membrane polarity. Considering that ZO-1’s primary role is to recruit other tight junction proteins (such as ZO-2 and ZO-3), forming complexes which, in turn, interact with actin filaments, disturbances in general cytoskeletal assembly and dynamics are likely to occur. On the other hand, ZO-1 localization as scattered dots or aggregates, possibly associated with lamellipodia or filopodia, rather than evenly distributed to the cell surface, suggests involvement of other cell adhesion molecules (e.g., nectin and cadherin systems), involved in filopodia extension and establishment of filopodia-lamellipodia contact sites [54]. Impaired cell-cell communication may also result in irregular paracellular flow with severe consequences on signaling pathways for proliferation and differentiation [55]. Relevantly, our observations well correlate with data previously obtained by RNA sequencing profiles and protein studies of the cytoskeletal constituents in RTD motor neurons, demonstrating perturbed neurofilament composition [56]. This fundamental aspect needs to be addressed in further details, to ascertain the relationship between cytoskeletal assembly and RF transport.

Noteworthy, electron micrographs demonstrate the presence of spheroidal vesicles, possibly exosomes, close to plasma membranes in RTD cells. These may be released as vectors of paracrine signals, with a protective role or as an intercellular communication mechanism, alternative to cell-cell direct contact [57].

Large vesicles are recognized next to the surface of RTD cells, especially from the most severely affected patient. These structures, reminiscent in shape and size of apoptotic bodies...
Figure 9: JC-1 staining images of Ctrl iPSCs and RTD iPSCs before and after RF treatment, showing the same field captured before and after 1, 5, 10, 15, and 30 min \( \text{H}_2\text{O}_2 \) exposure. (a) Regions of high mitochondrial polarization are revealed by red fluorescence due to J-aggregate formation, whereas depolarized regions are marked by green fluorescence of JC-1 monomers. Images show the time-dependent loss of red J-aggregate fluorescence and cytoplasmic diffusion of green monomer fluorescence following \( \text{H}_2\text{O}_2 \) administration. (b) Time course of cells following \( \text{H}_2\text{O}_2 \) exposure showing the fluorescence intensity ratio for JC-1 staining (red/green).
are readily detected in SEM images and may correspond to cell blebs and fragments, containing intact organelles or nuclear portions, occasionally observed in FIB/SEM samples. Noteworthy, induction of apoptotic cell death pathway has been recently associated to RF depletion [49].

4.2. RTD Affects Mitochondrial Morphofunctional Features. Since flavoenzymes are responsible for a wide array of energy metabolism pathways involving mitochondria, we addressed their possible dysfunction in patient-derived iPSCs. In the present study, we demonstrate abnormally high concentration of O$_2^-$, as assessed by MitoSOX probe, in RTD cell cultures. Such redox imbalance well correlates with our ultrastructural data, showing remarkably disrupted mitochondrial morphology, consistent with the relationship linking functional and morphological state [45, 59, 60]. Indeed, taking advantage of FIB/SEM technology, we observed profoundly altered mitochondrial cristae architecture in RTD cells. Further support to the hypothesized severely compromised energetic state in patient cells comes from JC-1 experiments, revealing abnormal mitochondrial polarization state. The key indicator of mitochondrial activity MMP is maintained at stable levels for normal cell functioning, and its prolonged perturbation, associated with changed levels of intracellular ATP, may lead to pathological consequences [61–63]. To this respect, our results on MMP, while invariably showing abnormal values consequent to RTD, intriguingly demonstrate opposite trends in the two patients: depolarization in RTD patient 1 and hyperpolarization in patient 2. Low MMP is generally associated with a failure in mitochondrial quality control, resulting from insufficient/defective systems of repair/removal of damaged organelles [64]. Whether turnover mechanisms, such as autophagy, are properly functioning in RTD condition is yet to be clarified. Ongoing work at our laboratories suggest abnormal activation of this process, in line with transcriptomic analysis performed on RTD MNs by Rizzo and coll. [56]. By contrast, mitochondrial hyperpolarization may lead to increased generation of ROS, in a self-sustaining loop detrimental to cell survival [65]. Paradoxically, hyperpolarization per se causes an increase of ATP demand in diseased cells [66]. While the reason for the different behavior of the two RTD cell cultures (associated with a mild or severe clinical condition) remains to be addressed, a possible explanation may refer to the different levels of CAT displayed by the two patients (see next subsection). Regardless, it should be noted that hyperpolarization and depolarization are both associated with abnormal states of respiration [64, 67]. In addition to this, we observed an increased number and size of mitochondria (as assessed by electron microscopy and a-mitochondria immunofluorescence analyses) in patients’ derived iPSCs, and we hypothesize that this is a response of patients’ cells to the altered redox status. In fact, increased number of iPSC mitochondria has also been observed in iPSCs aged in culture as a response to the aerobic environment [68].

4.3. ROS-Scavenging Systems Are Altered in RTD Cells. Data collected on mitochondrial morphofunctional features prompted us to address possible oxidative stress condition in RTD cells, with a focus on redox status and O$_2^-$ and H$_2$O$_2$-scavenging systems. This hypothesis was also driven by previous in vivo evidence that experimental dietary RF deficiency affects expression levels of antioxidant systems [50–52, 69–73]. We investigated the distribution of GSH and found its lower expression in RTD cells. While such decrease is easily explained by considering the implication of RF in GSH cycle, FAD is the coenzyme of glutathione reductase, which mediates regeneration of reduced GSH—it is worth noting that in diseased iPSCs, immunofluorescent dots appear sometimes aggregated. This suggests protein glutathionylation, possibly leading to proteasome/autophagic activation, an aspect that deserves further investigation.

Our confocal analysis shows significantly lower levels of SOD2 in RTD cells, as compared to their healthy counterparts. This result is in total agreement with and may in fact explain the increased number of damaged mitochondria, as assessed by FIB/SEM analysis, which are the ones presumably attacked by intraorganellar O$_2$ overproduction (in accordance with the MitoSOX data). We also investigated SOD1 levels, which are instead increased in RTD patients’ cells, supporting the view that O$_2^-$ mostly exerts its toxic function within mitochondria. Thus, it is conceivable that cytosolic O$_2^-$ is efficiently scavenged by SOD1, however posing the additional problem, as to whether H$_2$O$_2$ resulting from its dismutation undergoes equally efficient removal by CAT, its major detoxifying enzyme [74, 75]. RTD cells show higher CAT levels, suggestive of a response mechanism, possibly triggered by redox sensors, such as the transcription factor NRF2. In the most severe RTD form, this induction is highly significant and may account for the unusual response to H$_2$O$_2$ insult, leading to the hyperpolarized state detected in JC-1 assay. To this respect, it is worth mentioning that immunofluorescence observations intriguingly suggest the presence of cytosolic CAT, beside its expected peroxisomal localization. Such uncommon distribution may in fact reflect the susceptibility to oxidative stress of CAT import machinery, involving a noncanonical PTS1 signal. Specifically, the peroxisomal import receptor peroxin 5 (PEX5) was shown to function as a stress sensor, retaining CAT in the cytosol in oxidative stress conditions [76]. Interestingly, the same authors bring evidence that cytosolic CAT can protect against H$_2$O$_2$-mediated redox changes, thus constituting a cellular defense mechanism to combat oxidative insults of extra-peroxisomal (possibly including mitochondrial) origin.

4.4. Downregulation of Peroxisomal Proteins in RTD Cells Suggests Lipid Dysmetabolism. Interplay of mitochondria with peroxisomes is receiving growing attention, in view of their cooperative roles in regulating redox signaling pathways and in sustaining metabolic homeostasis. In addition to ROS metabolism, to which both scavengers (namely, CAT, classical peroxisomal marker) and ROS-producing oxidases contribute, peroxisomes are responsible for other energy metabolism pathways, such as fatty acid β-oxidation. We addressed the involvement of acyl-CoA oxidase (ACOX-1) and 3-oxoacyl-CoA thiolase (ACAA-1, thiolase), catalyzing the first and the last step of peroxisomal
Based on confocal analysis, downregulation of ACOX1 in patients’ cells, as compared to Ctrl, is demonstrated, while thiolase levels are unchanged. Since ACOX-1 is the rate-limiting enzyme of peroxisomal β-oxidation cycle, overall decreased efficiency in metabolizing very long-chain fatty acids likely occurs. Such an impairment would also result from limited availability of the obligate cofactor FAD, due to RTD condition. Even data collected for PMP70, a major component of peroxisomal membranes and crucial fatty acid translocator, argue for lipid dysmetabolism. In fact, confocal microscopic analysis reveals a decreased immunoreactivity, possibly indicating the lack of import-competent peroxisomes. Moreover, the ultrastructural analysis aimed at identifying the peroxisomal population supports a relatively low presence of peroxisomes in RTD cells. Besides, disturbed peroxisomal biogenesis would also be supported by mislocalization in RTD cells of CAT (cytosolic) and ACAA1 (as large aggregates), possibly driven by oxidative damage and cytoskeletal derangement. To this respect, it is worth mentioning that our knowledge of the peroxisome interaction with the cytoskeleton has dramatically increased. Indeed, attachment of peroxisomes to cytoskeleton and movement along microtubular filaments and actin cables are essential and highly regulated processes enabling metabolic efficiency, biogenesis, maintenance, and inheritance of this dynamic cellular compartment [77].

The observed downregulation of peroxisomal lipid metabolism in RTD cells well correlates with in vivo experimental studies demonstrating the negative effect of RF deficiency on β-oxidation enzyme activity [71, 72, 78]. On the other hand, our data are consistent with the proposed role of RF in controlling lipid metabolism pathways through gene expression regulation at diverse levels [43, 44].

4.5. RF Treatment Restores RTD Cell Phenotype and Redox Status. Clinical studies by Bosch and coll. [23] brought evidence that therapeutic use of RF extends RTD patients’ life expectancy, ameliorating neurological symptoms. Based on these empirical studies and on our results on redox imbalance, we performed RF treatment on patient-specific iPSCs. Vitamin supplementation ameliorates RTD phenotype, particularly as regards mitochondrial ultrastructure. Consistently, such treatment was able to revert O2⁻ concentration, as assessed by MitoSOX assay, to normal levels. RF ability in restoring redox status is compatible with its proposed ROS-scavenging role, through an either direct or indirect action, as a component of glutathione redox cycle [46, 47, 79, 80].

Such beneficial effects support the hypothesized cooperation among different RFVT isoforms, particularly involving, in our iPSC model, dimerization of RFVT1 and RFVT2 to accomplish RF uptake [44]. Nonetheless, we cannot rule out some residual uptake activity of the mutated protein. Further studies are needed to ascertain these hypotheses.

5. Conclusions

Human iPSCs represent an innovative model for numerous clinical studies, opening new perspectives of research and applications in the biomedical field. Moreover, the generation of iPSCs from patients affected with rare genetic disease allows to overcome ethical and technical problems due to manipulation of stem cells, allowing for site-specific genetic correction. In the present study, we took advantage of iPSC technology to shed light on the morphofunctional mechanisms underlying RTD syndrome, a rare neurodegenerative disorder caused by loss-of-function mutation in two RF transporter genes.
While supporting the innovative potential of our iPSC model of RTD, our work demonstrates concurrent mitochondrial/peroxisomal alterations in the disease. The dramatic changes here reported range from cell junctional contacts, possibly involving cytoskeletal assembly, to altered MMP, with consequent oxidative stress and antioxidant response, to disturbed peroxisomal biogenesis and metabolism (Figure 10). Since our study represents to our knowledge the first to address the distribution of peroxisomal population in iPSCs, further investigation on this topic is encouraged, especially in view of the interplay with the cytoskeleton and other cell compartments, namely, ER and mitochondria [77, 81, 82].

Our findings, highlighting multiple defects contributing redox imbalance and energy dysmetabolism in RTD syndrome, may also explain specific manifestations of different diseases sharing defects in RF absorption or metabolism. Also, extending to the cellular level, the empirical studies by Bosch and coll. [23] will hopefully open new perspectives in dissecting the pathomechanisms of disease and in refining patient-specific, RF-based therapeutic strategies.

Data Availability

The data used to support the findings of this study are either included within the article or available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Claudia Compagnucci and Sandra Moreno contributed equally to this work.

Acknowledgments

The authors wish to thank Dr. Rossella Borghi for the support with MitoSOX assay and Dr. Daniele De Felicis, Dr. Giulia Scarparo, Dr. Maurizio Muzzi, and Prof. Andrea Di Giulio (LIME), for the helpful advice on FIB/SEM technology. Our appreciation also goes to Dr. Lorena Tragagnì for the support with DNA sequencing and to Dr. Zulema Percario, for the skillful technical assistance in confocal microscopy. We finally wish to gratefully acknowledge Prof. Maria Adelaide Micci (UTMB, Galveston, TX), for the advice in the interpretation of morphological data. FC is a recipient of MIUR fellowships for a PhD program at Roma Tre University. This study was also supported by Cure RTD Foundation; Fondazione Bambino Gesù; Ricerca Corrente, Italian Ministry of Health (Cinquè per mille); and the Grant of Excellence Department received by MIUR from Department of Science, University of Roma Tre.

Supplementary Materials

Figure S1: ultrastructural features of iPSCs from Ctrl and RTD patients, with reference to the presence of peroxisomes. Figure S2: dose-response effect of RF treatment assessed by MitoSOX Red assay. (Supplementary materials)

References

[1] L. Michaelis, M. P. Schubert, and C. V. Smythe, “Potentiometric study of the flavins,” The Journal of Biological Chemistry, vol. 116, pp. 587–607, 1936.
[2] A. M. Edwards, “Structure and general properties of flavins,” Methods in Molecular Biology, vol. 1146, pp. 3–13, 2014.
[3] H. J. Powers, “Riboflavin (vitamin B-2) and health,” The American Journal of Clinical Nutrition, vol. 77, no. 6, pp. 1352–1360, 2003.
[4] H. J. Powers, B. M. Corfe, and E. Nakano, “Riboflavin in development and cell fate,” Sub-Cellular Biochemistry, vol. 56, pp. 229–245, 2012.
[5] S. Balasubramaniam, J. Christodoulou, and S. Rahman, “Disorders of riboflavin metabolism,” Journal of Inherited Metabolic Disease, vol. 42, no. 4, pp. 608–619, 2019.
[6] V. Massey, “The chemical and biological versatility of riboflavin,” Biochemical Society Transactions, vol. 28, no. 4, pp. 283–296, 2000.
[7] F. Depeint, W. R. Bruce, N. Shangari, R. Mehta, and P. J. O’Brien, “Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism,” Chemical-Biological Interactions, vol. 163, no. 1-2, pp. 94–112, 2006.
[8] M. Barile, T. A. Giancasis, P. Leone, M. Galuccio, and C. Indiveri, “Riboflavin transport and metabolism in humans,” Journal of Inherited Metabolic Disease, vol. 39, no. 4, pp. 545–557, 2016.
[9] M. Islinger, A. Voelkl, H. D. Fahimi, and M. Schrader, “The peroxisome: an update on mysteries 2.0,” Histochemistry and Cell Biology, vol. 150, no. 5, pp. 443–471, 2018.
[10] R. J. A. Wanders, “Metabolic functions of peroxisomes in health and disease,” Biochimie, vol. 98, pp. 36–44, 2014.
[11] M. Schrader, M. Kamoshita, and M. Islinger, “Organelle interplay-peroxisome interactions in health and disease,” Journal of Inherited Metabolic Disease, vol. 43, no. 1, pp. 71–89, 2019.
[12] R. J. A. Wanders, H. R. Waterham, and S. Ferdinandesse, “Peroxisomes and their central role in mitochondrial interaction networks in humans,” Sub-Cellular Biochemistry, vol. 89, pp. 345–365, 2018.
[13] P. M. Mullineaux, M. Exposito-Rodriguez, P. P. Laissue, and N. Smirnoff, “ROS-dependent signalling pathways in plants and algae exposed to high light: comparisons with other eukaryotes,” Free Radical Biology & Medicine, vol. 122, pp. 52–64, 2018.
[14] D. B. McCormick, “Two interconnected B vitamins: riboflavin and pyridoxine,” Physiological Reviews, vol. 69, no. 4, pp. 1170–1198, 1989.
[15] H. M. Said, “Intestinal absorption of water-soluble vitamins in health and disease,” The Biochemical Journal, vol. 437, no. 3, pp. 357–372, 2011.
[16] A. Yonezawa and K. Inui, “Novel riboflavin transporter family RFVT/SLC52: identification, nomenclature, functional
characterization and genetic diseases of RFVT/SLC52," Molecular Aspects of Medicine, vol. 34, no. 2-3, pp. 693–701, 2013.

[17] M. Barile, T. A. Giansaspero, C. Brizio et al., "Biosynthesis of flavin cofactors in man: implications in health and disease," Current Pharmaceutical Design, vol. 19, no. 14, pp. 2649–2675, 2013.

[18] V. S. Subramanian, S. Sabui, C. W. Heskett, and H. M. Said, "Sodium butyrate enhances intestinal riboflavin uptake via induction of expression of riboflavin transporter-3 (RFVT3)," Digestive Diseases and Sciences, vol. 64, no. 1, pp. 84–92, 2019.

[19] A. M. L. Wu, L. Dedina, P. Dalvi et al., "Riboflavin uptake transporter SLC52a2 (RFVT2) is upregulated in the mouse mammary gland during lactation," American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, vol. 310, no. 7, pp. R578–R585, 2016.

[20] S. Mosegaard, G. H. Bruun, K. F. Flyvbjerg et al., "An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency," Molecular Genetics and Metabolism, vol. 122, no. 4, pp. 182–188, 2017.

[21] Y. Moriyama, "Riboflavin transporter is finally identified," Journal of Biochemistry, vol. 150, no. 4, pp. 341–343, 2011.

[22] D. B. McCormick, "The fate of riboflavin in the mammal," Nutrition Reviews, vol. 30, no. 4, pp. 75–79, 1972.

[23] A. M. Bosch, N. G. G. M. Abeling, L. Illst et al., "Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment," Journal of Inherited Metabolic Disease, vol. 34, no. 1, pp. 159–164, 2011.

[24] B. O’Callaghan, A. M. Bosch, and H. Houlden, "An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency," Journal of Inherited Metabolic Disease, vol. 42, no. 4, pp. 598–607, 2019.

[25] F. Amir, C. Atzinger, K. Massey et al., "The clinical journey of patients with riboflavin transporter deficiency type 2," Journal of Child Neurology, vol. 35, no. 4, pp. 283–290, 2020.

[26] P. Green, M. Wiseman, Y. J. Crowe et al., "Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54," American Journal of Human Genetics, vol. 86, no. 3, pp. 485–489, 2010.

[27] B. Jaeger and A. M. Bosch, "Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience," Journal of Inherited Metabolic Disease, vol. 39, no. 4, pp. 559–564, 2016.

[28] T. Udhayabanu, A. Manole, M. Rajeshwari, P. Varalakshmi, H. Houlden, and B. Ashokkumar, "Riboflavin responsive mitochondrial dysfunction in neurodegenerative diseases," Journal of Clinical Medicine, vol. 6, no. 5, p. 52, 2017.

[29] S. Sabui, V. S. Subramanian, Q. Pham, and H. M. Said, "Identification of transmembrane protein 237 as a novel interactor with the intestinal riboflavin transporter-3 (RFVT-3): role in functionality and cell biology," American Journal of Physiology. Cell Physiology, vol. 316, no. 6, pp. C805–C814, 2019.

[30] H. Yoshimatsu, A. Yonezawa, K. Yamanishi et al., "Disruption of SLC52A3 gene causes neonatal lethality with riboflavin deficiency in mice," Scientific Reports, vol. 6, no. 1, 2016.

[31] A. Intoh, N. Suzuki, K. Koszka, and K. Eggan, "SLC52A3, a Brown-Vialetto-Van Laere syndrome candidate gene is essential for mouse development, but dispensable for motor neuron differentiation," Human Molecular Genetics, vol. 25, no. 9, pp. 1814–1823, 2016.

[32] P. Karagiannis, K. Takahashi, M. Saito et al., "Induced pluripotent stem cells and their use in human models of disease and development," Physiological Reviews, vol. 99, no. 1, pp. 79–114, 2019.

[33] R. Godini, H. Y. Lafta, and H. Fallahi, "Epigenetic modifications in the embryonic and induced pluripotent stem cells," Gene Expression Patterns, vol. 29, pp. 1–9, 2018.

[34] J. Mathieu and H. Ruohola-Baker, "Metabolic remodeling during the loss and acquisition of pluripotency," Development, vol. 144, no. 4, pp. 541–551, 2017.

[35] A. Rastogi, P. Joshi, E. Contreras, and V. Gama, "Remodeling of mitochondrial morphology and function: an emerging hallmark of cellular reprogramming," Cell Stress, vol. 3, no. 6, pp. 181–194, 2019.

[36] J. Prieto and J. Torres, "Mitochondrial dynamics: in cell reprogramming as it is in cancer," Stem Cells International, vol. 2017, Article ID 8073721, 11 pages, 2017.

[37] J. O. Johnson, J. R. Gibbs, A. Megarbane et al., "Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease," Brain, vol. 135, no. 9, pp. 2875–2882, 2012.

[38] T. B. Haack, C. Makowski, Y. Yao et al., "Impaired riboflavin transport due to missense mutations in SLC52A2 causes Brown-Vialetto-Van Laere syndrome," Journal of Inherited Metabolic Disease, vol. 35, no. 6, pp. 943–948, 2012.

[39] A. R. Foley, M. P. Menezes, A. Pandraud et al., "Treatable childhood neuropathony caused by mutations in riboflavin transporter RFVT2," Brain, vol. 137, no. 1, pp. 44–56, 2014.

[40] J. Cosgrove, S. Datta, and M. Bushby, "Adult onset Brown-Vialetto-Van Laere syndrome with opsoclonus and a novel heterozygous mutation: a case report," Clinical Neurology and Neurosurgery, vol. 128, pp. 1–3, 2015.

[41] A. Davis, D. Josifova, S. Lloyd-Owen, A. Radunovic, and M. Swash, "Brown-Vialetto-Van Laere syndrome: a 28-year follow-up," Journal of Neurology, Neurosurgery, and Psychiatry, vol. 87, no. 6, pp. 681–682, 2016.

[42] A. Manole, Z. Jaunnuktane, I. Hargreaves et al., "Clinical, pathological and functional characterization of riboflavin-responsive neuropathy," Brain, vol. 140, no. 11, pp. 2820–2837, 2017.

[43] A. K. Bamaga, R. N. Maamari, S. M. Culican, M. Shinawi, and P. T. Golumbek, "Child neurology: Brown-Vialetto-Van Laere syndrome: dramatic visual recovery after delayed riboflavin therapy," Neurology, vol. 91, no. 20, pp. 938–941, 2018.

[44] M. Ciccoletta, S. Corti, M. Catteruccia et al., "Riboflavin transporter 3 involvement in infantile Brown-Vialetto-Van Laere disease: two novel mutations," Journal of Medical Genetics, vol. 50, no. 2, pp. 104–107, 2013.

[45] F. Colafranceschi, M. Monti, F. Bolletta et al., "Senescence-associated ultrastructural features of long-term cultures of induced pluripotent stem cells (iPSCs)," Aging (Albany NY), vol. 9, no. 10, pp. 2209–2222, 2017.

[46] M. Ashoori and A. Saedsomeolia, "Riboflavin (vitamin B2) and oxidative stress: a review," The British Journal of Nutrition, vol. 111, no. 11, pp. 1985–1991, 2014.

[47] J. T. Pinto and J. Zempleni, "Riboflavin," Advances in Nutrition, vol. 7, no. 5, pp. 973–975, 2016.

[48] M. Nagao and K. Tanaka, "FAD-dependent regulation of transcription, translation, post-translational processing, and
post-processing stability of various mitochondrial acyl-CoA dehydrogenases and of electron transfer flavoprotein and the site of holoenzyme formation,” *The Journal of Biological Chemistry*, vol. 267, no. 25, pp. 17925–17932, 1992.

[49] L. A. Cogburn, D. N. Smarsh, X. Wang, N. Trakooljul, W. Carré, and H. B. White, “Transcriptional profiling of liver in riboflavin-deficient chicken embryos explains impaired lipid utilization, energy depletion, massive hemorrhaging, and delayed feathering,” *BMC Genomics*, vol. 19, no. 1, p. 177, 2018.

[50] H. Hirano, S. Hamajima, S. Horiuichi, Y. Niitsu, and S. Ono, “Effects of B2-deficiency on lipoperoxide and its scavenging system in the rat lens,” *International Journal for Vitamin and Nutrition Research*, vol. 53, no. 4, pp. 377–382, 1983.

[51] P. Tumkiratiwong, R. Tuntrongchitr, P. Migasena et al., “Antioxidant enzyme levels in the erythrocytes of riboflavin-deficient and Trichinella spiralis-infected rats,” *The Southeast Asian Journal of Tropical Medicine and Public Health*, vol. 34, pp. 480–485, 2003.

[52] G. Wang, W. Li, X. Lu, and X. Zhao, “Riboflavin alleviates cardiac failure in type I diabetic cardiomyopathy,” *Heart International*, vol. 6, no. 2, p. h1.2011.e21, 2018.

[53] T. C. Lin, Y. Y. Lin, C. C. Hsu et al., “Nanomedicine-based curcumin approach improved ROS damage in best dystrophy,” *PLoS One*, vol. 8, no. 10, article e76201, 2013.

[54] I. Kratzer, A. Vasiljevic, C. Rey et al., “Complexity and developmental changes in the expression pattern of claudins at the blood-CSF barrier,” *Histochemistry and Cell Biology*, vol. 138, no. 6, pp. 861–879, 2012.

[55] F. Rizzo, A. Ramirez, C. Compagnucci et al., “Genome-wide RNA sequencing of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown-Vialetto disease that is partially rescued by riboflavin,” *Scientific Reports*, vol. 7, no. 1, 2017.

[56] Y. Wang, L. Zhang, Y. Li et al., “Exosomes/ microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium,” *International Journal of Cardiology*, vol. 192, pp. 61–69, 2015.

[57] Z. Sladek and D. Rysank, “Apoptosis of resident and inflammatory macrophages before and during the inflammatory response of the virgin bovine mammary gland,” *Acta Veterinaria Scandinavica*, vol. 52, no. 1, 2010.

[58] C. R. Hackenbrock, “Ultrastructural bases for metabolically linked mechanical activity in mitochondria. I. Reversible ultrastructural changes with change in metabolic steady state in isolated liver mitochondria,” *The Journal of Cell Biology*, vol. 30, no. 2, pp. 269–297, 1966.

[59] S. T. Suhr, E. A. Chang, T. Jjong et al., “Mitochondrial rejuvenation after induced pluripotency,” *PLoS One*, vol. 5, no. 11, article e14095, 2010.

[60] N. Zamzami, P. Marchetti, M. Castedo et al., “Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death,” *The Journal of Experimental Medicine*, vol. 182, no. 2, pp. 367–377, 1995.

[61] D. S. Izyumov, A. V. Avetisyan, O. Y. Pletjushkina et al., “Wages of Fear!” transient threefold decrease in intracellular ATP level imposes apoptosis,” *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, vol. 1658, no. 1-2, pp. 141–147, 2004.

[62] D. B. Zorov, M. Juhaszova, and S. J. Sollott, “Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release,” *Physiological Reviews*, vol. 94, no. 3, pp. 909–950, 2014.

[63] D. B. Zorov, V. A. Popkov, E. Y. Plotnikov et al., “Mitochondrial membrane potential,” *Analytical Biochemistry*, vol. 552, pp. 50–59, 2018.

[64] M. Juhaszova, D. B. Zorov, S. H. Kim et al., “Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore,” *The Journal of Clinical Investigation*, vol. 113, no. 11, pp. 1535–1549, 2004.

[65] S. Zakharenko and S. Popov, “Plasma membrane recycling and flow in growing neurites,” *Neuroscience*, vol. 97, no. 1, pp. 185–194, 2000.

[66] D. M. Wolf, M. Segawa, A. K. Kondadi et al., “Individual crises within the same mitochondrion display different membrane potentials and are functionally independent,” *EMBO Journal*, vol. 38, no. 22, article e101056, 2019.

[67] A. Masotti, A. Celluzzi, S. Petrini, E. Bertini, G. Zanni, and C. Compagnucci, “Aged iPSCs display an uncommon mitochondrial appearance and fail to undergo in vitro neurogenesis,” *Aging (Albany NY)*, vol. 6, no. 12, pp. 1094–1108, 2014.

[68] T. Okayasu, K. Kameda, T. Ono, and Y. Imai, “Effects of dietary vitamin B-2 and vitamin E on the delta9-desaturase and catalase activities in the rat liver microsomes,” *Biochimica et Biophysica Acta*, vol. 489, no. 3, pp. 397–402, 1977.

[69] S.-S. Lee, J. Ye, D. P. Jones, and D. B. McCormick, “Correlation of H2O2 production and liver catalase during riboflavin deficiency and repletion in mammals,” *Biochemical and Biophysical Research Communications*, vol. 117, no. 3, pp. 788–793, 1983.

[70] M. TANIGUCHI and T. HARM, “Effects of riboflavin and selenium deficiencies on glutathione and its relating enzyme activities with respect to lipid peroxide content of rat livers,” *Journal of Nutritional Science and Vitaminology (Tokyo)*, vol. 29, no. 3, pp. 283–292, 1983.

[71] G. Levin, U. Cogan, Y. Levy, and S. Mokady, “Riboflavin deficiency and the function and fluidity of rat erythrocyte membranes,” *The Journal of Nutrition*, vol. 120, no. 8, pp. 857–861, 1990.

[72] J. Huang, L. Tian, X. Wu, H. Yang, and Y. Liu, “Effects of dietary riboflavin levels on antioxidant defense of the juvenile grouper Epinephelus coioides,” *Fish Physiology and Biochemistry*, vol. 36, no. 1, pp. 55–62, 2010.

[73] E. Cadenas and K. J. A. Davies, “Mitochondrial free radical generation, oxidative stress, and aging,” *Free Radical Biology & Medicine*, vol. 29, no. 3-4, pp. 222–230, 2000.

[74] C. L. Walker, L. C. D. Pomatto, D. N. Tripathi, and K. J. A. Davies, “Redox regulation of homeostasis and proteostasis in peroxisomes,” *Physiological Reviews*, vol. 98, no. 1, pp. 89–115, 2018.

[75] P. A. Walton, C. Brees, C. Lismont, O. Apanasets, and M. Fransen, “The peroxisomal import receptor PEX5 functions as a stress sensor, retaining catalase in the cytosol in times of oxidative stress,” *Biochim Biophys Acta Mol Cell Res.*, vol. 1864, no. 10, pp. 1833–1843, 2017.
A. Neuhaus, C. Eggeling, R. Erdmann, and W. Schliebs, "Why do peroxisomes associate with the cytoskeleton?," *Biochimica et Biophysica Acta*, vol. 1863, no. 5, pp. 1019–1026, 2016.

S. Horiuchi, H. Hirano, and S. Ono, "Reduced and oxidized glutathione concentrations in the lenses of riboflavin-deficient rats," *Journal of Nutritional Science and Vitaminology*, vol. 30, no. 4, pp. 401–403, 1984.

K. Iwanaga, T. Hasegawa, D. E. Hultquist et al., "Riboflavin-mediated reduction of oxidant injury, rejection, and vasculopathy after cardiac allotransplantation," *Transplantation*, vol. 83, no. 6, pp. 747–753, 2007.

K. Thakur, S. K. Tomar, A. K. Singh, S. Mandal, and S. Arora, "Riboflavin and health: a review of recent human research," *Critical Reviews in Food Science and Nutrition*, vol. 57, no. 17, pp. 3650–3660, 2017.

M. Fransen, C. Lismont, and P. Walton, "The peroxisome-mitochondria connection: how and why?," *International Journal of Molecular Sciences*, vol. 18, no. 6, p. 1126, 2017.

Y. Wang, J. Metz, J. L. Costello et al., "Intracellular redistribution of neuronal peroxisomes in response to ACBD5 expression," *PLoS One*, vol. 13, no. 12, article e0209507, 2018.